| SMN | second malignant neoplasm; stathmin |
|---|---|
| TP | temperature and pressure; temperature probe; temporal peak; temporoparietal; tension pneumothorax; t... |
| TPF | thymus permeability factor; thymus to peak flow; true positive fraction |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| CBN | cannabinol; central benign neoplasm; Commission on Biological Nomenclature |
| antibodies, neoplasm | Immunoglobulins induced by antigens specific for tumours other than the normally occurring histocompatibility antigens. (12 Dec 1998) |
|---|---|
| antigens, neoplasm | Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumour cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. (12 Dec 1998) |
| brain neoplasm | Neoplasms of the part of the central nervous system contained within the cranium. (12 Dec 1998) |
| genes, structural, neoplasm | DNA sequences that code for RNA and for the proteins required for the enzymatic and structural function of neoplastic cells. (12 Dec 1998) |
| mucinous cystic neoplasm of pancreas | <radiology> = macrocystic adenoma of pancreas, cystadenoma / cystadenocarcinoma, M:F = 1:9, 40-60 years of age, malignant or pre-malignant, large mass (mean 12 cm), multilocular cysts, thick septations, tail / body in 85% (unlike adenocarcinoma and microcystic adenoma), hypo-/avascular, Differential diagnosis: panc pseudocyst, ** Cf: microcystic adenoma (12 Dec 1998) |
| histoid neoplasm | Old term for a neoplasm characterised by a cytohistologic pattern that closely resembles the tissue from which the neoplastic cells are derived. (05 Mar 2000) |
| neoplasm | <oncology, pathology> New and abnormal growth of tissue, which may be benign or cancerous. (16 Dec 1997) |
| neoplasm circulating cells | Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumours. (12 Dec 1998) |
| neoplasm: gallium imaging | <radiology> Useful: Hodgkin disease and histiocytic form of NHL poor sensitivity below the diaphragm, Burkitt lymphoma: almost 100% sensitivity, hepatoma: 90% sensitivity, melanoma: 90% sensitivity, leukaemia possibly useful: NHL: good for large and mediastinal lesions, nodal metastases from seminoma and embryonal cell carcinoma: 87% sensitivity, non-small cell lung CA: 85% sensitive not useful: head and neck, GI (especially adenocarcinoma), breast, gynaecological, kiddie tumours see: gallium: indications (12 Dec 1998) |
| neoplasm invasiveness | Ability of neoplasms to infiltrate and actively destroy surrounding tissue. (12 Dec 1998) |
| neoplasm metastasis | The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. The ability to metastasize is characteristic of all malignant neoplasms. (12 Dec 1998) |
| neoplasm recurrence, local | The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. (12 Dec 1998) |
| neoplasm regression, spontaneous | Disappearance of a neoplasm or neoplastic state without the intervention of therapy. (12 Dec 1998) |
| neoplasm, residual | Remnant of a tumour or cancer after primary, potentially curative therapy. (dr. Daniel masys, written communication) (12 Dec 1998) |
| neoplasm seeding | The local implantation of tumour cells by contamination of instruments and surgical equipment during and after surgical resection, resulting in local growth of the cells and tumour formation. (12 Dec 1998) |